Rani Therapeutics Holdings, Inc. (RANI)
0.8527
+0.01
(+1.51%)
USD |
NASDAQ |
Aug 31, 11:27
Rani Therapeutics Holdings Debt to Equity Ratio : 0.0905 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0905 |
| March 31, 2026 | 0.1387 |
| December 31, 2025 | 0.1308 |
| September 30, 2025 | -2.233 |
| June 30, 2025 | -3.878 |
| March 31, 2025 | -8.400 |
| December 31, 2024 | 14.91 |
| September 30, 2024 | 10.81 |
| June 30, 2024 | 12.43 |
| March 31, 2024 | 4.786 |
| December 31, 2023 | 2.339 |
| Date | Value |
|---|---|
| September 30, 2023 | 1.725 |
| June 30, 2023 | 1.264 |
| March 31, 2023 | 0.997 |
| December 31, 2022 | 0.8198 |
| September 30, 2022 | 0.3648 |
| June 30, 2022 | 0.0209 |
| March 31, 2022 | 0.0217 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -1.576 |
| March 31, 2021 | -1.645 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Fulcrum Therapeutics, Inc. | 0.017 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 60.84M |
| Total Liabilities (Quarterly) | 12.86M |
| Shareholders Equity (Quarterly) | 39.23M |
| Current Ratio | 5.313 |
| Net Debt Paydown Yield | 5.17% |